29
Sat, Apr
19 New Articles

WuXi AppTec Acquires Biology Focused R&D Service Leader HD Biosciences

Industry Reports
Typography

WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform announced that it has acquired HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO).

After completion of acquisition, HD Biosciences will become a wholly-owned subsidiary of WuXi, and will continue to focus on growing its core competences and providing greater services. The acquisition will further strengthen WuXi’s R&D capability from target validation to lead discovery and optimization, improving and expanding WuXi’s open-access enabling service platform.

Founded in 2002, HD Biosciences is headquartered in Shanghai with operating facilities in Beijing and San Diego, USA. As a leading biology and preclinical service provider, its plate-based pharmacology & screening capability and AGMTM based target validation are industry leading platforms with great reputation. The company also provides hit identification, lead discovery, in vivo pharmacology and other related services.

HD Biosciences has long established close and strategic partnerships with major multinational pharmaceutical companies, biotechs and research institutions worldwide. Over the years, HD Biosciences has been providing award winning services to its worldwide clients, and has won a leading position among the biology CROs in China.

“We are excited about this acquisition and the great opportunities it brings along. HB Biosciences has a long-standing mission to grow into a major global player with distinctive core competences that could create special value for our clients. Merging with WuXi AppTec, a clear industry leader in drug R&D enabling services with enormous global exposure, resources and vision, will greatly speed up the process. We are confident that the integration will elevated our services to a new height and will enable us to better meet our growing customer needs,” said Dr. Xuehai Tan, Chairman and CEO of HD Biosciences.

“We are very pleased to welcome HD Biosciences to WuXi,” said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi AppTec. “During the past 14 years, HD Biosciences has developed into a global company with wide recognition, and this business combination is an important step in strengthening WuXi’s biology and preclinical service capability. At WuXi, our commitment is to build the most comprehensive capability and technology platform in industry to enable anyone, and any company to discover and develop better medicines and healthcare products for patients, and to realize our vision that every drug can be made and every disease can be treated.”

About WuXi AppTec
WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics, WuXi platform is enabling nearly 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated."  Please visit http://www.wuxiapptec.com

Media Contacts:
Sunnie Sun, WuXi AppTec
+86-21-5046-5030
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Market Movers

Rogers Corporation

NYQ : ROG - 28 Apr, 4:02pm
102.94
+0.36 (+0.35%) After Hours:
Open 103.61 Mktcap 1.86B
High 106.20 52wk Hight 106.20
Low 102.84 52wk Low 51.98
Vol 254103 Avg Vol 130519
Eps 5.03 P/e 38.85
Currency: USD

Banco Santander, S.A. Sponsored

NYQ : SAN - 28 Apr, 4:01pm
6.52
+0.07 (+1.09%) After Hours:
Open 6.59 Mktcap 95.07B
High 6.60 52wk Hight 6.63
Low 6.51 52wk Low 3.60
Vol 6.75M Avg Vol 7.11M
Eps 0.49 P/e 14.95
Currency: USD

Merck & Company, Inc. (new)

NYQ : MRK - 28 Apr, 4:00pm
62.33
-0.25 (-0.40%) After Hours:
Open 62.58 Mktcap 171.13B
High 62.65 52wk Hight 66.80
Low 62.14 52wk Low 53.06
Vol 9.46M Avg Vol 9.03M
Eps 3.81 P/e 44.21
Currency: USD

Johnson & Johnson

NYQ : JNJ - 28 Apr, 4:02pm
123.47
-0.27 (-0.22%) After Hours:
Open 123.85 Mktcap 335.02B
High 123.90 52wk Hight 129.00
Low 123.13 52wk Low 109.32
Vol 4.38M Avg Vol 6.70M
Eps 7.10 P/e 20.75
Currency: USD

Pfizer, Inc.

NYQ : PFE - 28 Apr, 4:01pm
33.92
+0.06 (+0.18%) After Hours:
Open 33.88 Mktcap 201.89B
High 33.94 52wk Hight 37.39
Low 33.75 52wk Low 29.83
Vol 15.98M Avg Vol 23.05M
Eps 2.55 P/e 28.92
Currency: USD

Direxion Daily 10-Yr Treasury B

PCX : TYO - 28 Apr, 8:00pm
14.32
-0.05 (-0.35%) After Hours:
Open 14.42 Mktcap
High 14.42 52wk Hight 16.29
Low 14.30 52wk Low 12.60
Vol 17778 Avg Vol 10849
Eps P/e
Currency: USD
Sign up via our free email subscription service to receive notifications when new information is available.
captcha